XML 67 R59.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

License and Collaboration Agreements - Additional Information (Detail) |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | 44 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Nov. 30, 2020 USD ($) | Oct. 27, 2020 USD ($) | Jan. 31, 2024 USD ($) | Oct. 31, 2023 USD ($) | Apr. 30, 2023 USD ($) | Jan. 31, 2023 USD ($) | Jun. 30, 2022 USD ($) | Apr. 30, 2022 USD ($) | Aug. 31, 2021 USD ($) | Jun. 30, 2024 USD ($) License | Jun. 30, 2023 USD ($) | Jun. 30, 2024 USD ($) License | Jun. 30, 2023 USD ($) | Dec. 31, 2023 USD ($) | Jun. 30, 2024 USD ($) License | Jan. 31, 2021 USD ($) | Oct. 31, 2020 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development cost reimbursement received |  |  | $ 15,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  |  |  | $ 199,685,000 | $ 94,969,000 | $ 372,009,000 | $ 139,814,000 |  |  |  |
Number of licensed products | License |  |  |  |  |  |  |  |  |  | 2 |  | 2 |  |  | 2 |  |
EMPAVELI [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  |  |  | $ 24,512,000 | 22,303,000 | $ 50,122,000 | 42,742,000 |  |  |  |
SYFOVRE [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  |  |  | 154,624,000 | 67,342,000 | 292,089,000 | 85,702,000 |  |  |  |
Royalty revenue |  |  |  |  |  |  |  |  |  |  |  | 9,500,000 |  |  |  |  |
Regulatory milestone payments |  |  | 3,000,000 | $ 2,000,000 | $ 2,300,000 |  |  |  |  |  |  |  |  |  |  |  |
Royalty expense incurred |  |  |  |  |  |  |  |  |  | 18,400,000 |  | 18,400,000 |  |  | $ 18,400,000 |  |
Royalty Expense |  |  |  |  |  |  |  |  |  |  |  | 9,500,000 |  |  |  |  |
Regulatory milestone incurred |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000,000 |  |  |
EMPAVELI and Aspaveli [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty revenue |  |  |  |  |  |  |  |  |  |  |  | 3,100,000 |  |  |  |  |
Milestone payments based on annual sales milestones |  |  | 1,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty expense incurred |  |  |  |  |  |  |  |  |  | 11,100,000 |  | 11,100,000 |  |  | 11,100,000 |  |
Royalty Expense |  |  |  |  |  |  |  |  |  |  |  | 3,100,000 |  |  |  |  |
Swedish Orphan Biovitrum AB (Publ) [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty Revenue |  |  |  |  |  |  |  |  |  | 4,400,000 | 2,400,000 | $ 8,900,000 | 4,000,000 |  |  |  |
Collaboration and License Agreement [Member] | Swedish Orphan Biovitrum AB (Publ) [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment | $ 250,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment received for achievement of regulatory development milestone |  |  |  |  |  |  |  | $ 50,000,000 |  |  |  |  |  |  |  |  |
Development cost reimbursement received |  |  |  |  |  | $ 65,000,000 |  |  |  |  |  |  |  |  |  |  |
Waived Payment |  |  | 15,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalties entitled to receive after first commercial sale of applicable licensed product period |  |  |  |  |  |  |  |  |  |  |  | 10 years |  |  |  |  |
Contract research and development reimbursement commitment |  | $ 80,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contract research and development expense |  |  |  |  |  |  |  |  |  | 0 | $ 0 | $ 0 | $ 0 |  | 65,000,000 |  |
Contract research and development current |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 15,000,000 |  |  |
Remaining reimbursement payment |  |  | 15,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and License Agreement [Member] | Swedish Orphan Biovitrum AB (Publ) [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate milestone payments upon achievement of specified one time regulatory development and commercial milestone events |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 915,000,000
Development cost reimbursement |  |  |  |  |  |  |  |  |  |  |  | 80,000,000 |  |  |  |  |
University of Pennsylvania [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual maintenance fees |  |  |  |  |  |  |  |  |  |  |  | 100,000 |  |  |  |  |
Development milestone achievement |  |  |  |  |  |  | $ 5,000,000 |  | $ 1,000,000 |  |  |  |  |  |  |  |
University of Pennsylvania [Member] | EMPAVELI and Aspaveli [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments based on annual sales milestones |  |  |  |  |  | $ 1,000,000 |  |  |  |  |  |  |  |  |  |  |
University of Pennsylvania [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate milestones payments |  |  |  |  |  |  |  |  |  | 3,200,000 |  | 3,200,000 |  |  | 3,200,000 |  |
Milestone payments based on annual sales milestones |  |  |  |  |  |  |  |  |  |  |  | 5,000,000 |  |  |  |  |
2010 License Agreement [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate milestones payments |  |  |  |  |  |  |  |  |  | $ 1,700,000 |  | 1,700,000 |  |  | $ 1,700,000 |  |
Milestone payments based on annual sales milestones |  |  |  |  |  |  |  |  |  |  |  | $ 2,500,000 |  |  |  |  |
Sobi Agreement and Another Licensing Transaction [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sublicense fee owed |  |  | $ 500,000 |  |  |  |  |  |  |  |  |  |  |  |  | $ 25,000,000 |

X
- Definition Aggregate milestone payments upon achievement of specified one time regulatory development and commercial milestone events. + References No definition available. + Details
Name: | apls_AggregateMilestonePaymentsUponAchievementOfSpecifiedOneTimeRegulatoryDevelopmentAndCommercialMilestoneEvents
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Annual license maintenance fees. + References No definition available. + Details
Name: | apls_AnnualLicenseMaintenanceFees
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contra research and development expense. + References No definition available. + Details
Name: | apls_ContraResearchAndDevelopmentExpense
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contract research and development current. + References No definition available. + Details
Name: | apls_ContractResearchAndDevelopmentCurrent
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Contract research and development reimbursement commitment. + References No definition available. + Details
Name: | apls_ContractResearchAndDevelopmentReimbursementCommitment
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Development cost reimbursement. + References No definition available. + Details
Name: | apls_DevelopmentCostReimbursement
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Development cost reimbursement received. + References No definition available. + Details
Name: | apls_DevelopmentCostReimbursementReceived
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Development milestone achievement. + References No definition available. + Details
Name: | apls_DevelopmentMilestoneAchievement
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payment received for achievement of regulatory development milestone. + References No definition available. + Details
Name: | apls_MilestonePaymentReceivedForAchievementOfRegulatoryDevelopmentMilestone
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of licensed products. + References No definition available. + Details
Name: | apls_NumberOfLicensedProducts
Namespace Prefix: | apls_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Regulatory milestone incurred based on achievement. + References No definition available. + Details
Name: | apls_RegulatoryMilestoneIncurredBasedOnAchievement
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Regulatory milestone payments based on achievement. + References No definition available. + Details
Name: | apls_RegulatoryMilestonePaymentsBasedOnAchievement
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Remaining reimbursement payment. + References No definition available. + Details
Name: | apls_RemainingReimbursementPayment
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Royalties entitled to receive after first commercial sale of applicable licensed product period. + References No definition available. + Details
Name: | apls_RoyaltiesEntitledToReceiveAfterFirstCommercialSaleOfApplicableLicensedProductPeriod
Namespace Prefix: | apls_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty expense incurred. + References No definition available. + Details
Name: | apls_RoyaltyExpenseIncurred
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Royalty revenue. + References No definition available. + Details
Name: | apls_RoyaltyRevenue
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sales milestone payments based on achievement of annual sales milestones. + References No definition available. + Details
Name: | apls_SalesMilestonePaymentsBasedOnAchievementOfAnnualSalesMilestones
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sublicense fee owed. + References No definition available. + Details
Name: | apls_SublicenseFeeOwed
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Upfront payment. + References No definition available. + Details
Name: | apls_UpfrontPayment
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Waived payment. + References No definition available. + Details
Name: | apls_WaivedPayment
Namespace Prefix: | apls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details
Name: | us-gaap_ContractualObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=apls_EmpaveliPegcetacoplanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=apls_SyfovreMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=apls_EmpaveliAndAspaveliMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=apls_SwedishOrphanBiovitrumABPublMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=apls_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=apls_UniversityOfPennsylvaniaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=apls_TwoThousandTenLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=apls_SobiAgreementAndAnotherLicensingTransactionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |